PTC Therapeutics, Inc. (PTCT): Price and Financial Metrics


PTC Therapeutics, Inc. (PTCT): $47.36

-0.01 (-0.02%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add PTCT to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

PTCT POWR Grades

  • PTCT scores best on the Value dimension, with a Value rank ahead of 87.78% of US stocks.
  • PTCT's strongest trending metric is Value; it's been moving up over the last 179 days.
  • PTCT's current lowest rank is in the Sentiment metric (where it is better than 7.89% of US stocks).

PTCT Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PTCT is -3.07 -- better than merely 3.68% of US stocks.
  • PTCT's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 1.72% of US stocks.
  • With a year-over-year growth in debt of -22.5%, PTC THERAPEUTICS INC's debt growth rate surpasses just 13.61% of about US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to PTC THERAPEUTICS INC are CPTN, BCRX, VLN, SPCE, and LXRX.
  • PTCT's SEC filings can be seen here. And to visit PTC THERAPEUTICS INC's official web site, go to www.ptcbio.com.

PTCT Valuation Summary

  • PTCT's price/sales ratio is 4.7; this is 123.81% higher than that of the median Healthcare stock.
  • PTCT's price/earnings ratio has moved down 8.9 over the prior 117 months.

Below are key valuation metrics over time for PTCT.

Stock Date P/S P/B P/E EV/EBIT
PTCT 2023-01-30 4.7 -14.4 -6.2 -8.0
PTCT 2023-01-27 4.8 -14.7 -6.3 -8.1
PTCT 2023-01-26 4.7 -14.6 -6.2 -8.1
PTCT 2023-01-25 4.8 -14.7 -6.3 -8.1
PTCT 2023-01-24 4.9 -15.0 -6.4 -8.3
PTCT 2023-01-23 4.9 -15.0 -6.4 -8.3

PTCT Growth Metrics

    Its 2 year net income to common stockholders growth rate is now at -78.67%.
  • Its year over year net income to common stockholders growth rate is now at -14.95%.
  • Its 5 year revenue growth rate is now at 255.98%.
Over the past 33 months, PTCT's revenue has gone up $389,637,000.

The table below shows PTCT's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 696.617 -259.531 -531.393
2022-06-30 618.233 -272.676 -555.702
2022-03-31 569.383 -248.579 -521.985
2021-12-31 538.593 -251.332 -523.901
2021-09-30 492.225 -246.858 -454.99
2021-06-30 471.886 -169.009 -391.058

PTCT's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • PTCT has a Quality Grade of C, ranking ahead of 45.84% of graded US stocks.
  • PTCT's asset turnover comes in at 0.235 -- ranking 183rd of 682 Pharmaceutical Products stocks.
  • NMTR, ZIOP, and ATXS are the stocks whose asset turnover ratios are most correlated with PTCT.

The table below shows PTCT's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.235 0.943 -0.271
2021-06-30 0.221 0.945 -0.205
2021-03-31 0.216 0.944 -0.305
2020-12-31 0.205 0.950 -0.360
2020-09-30 0.210 0.951 -0.473
2020-06-30 0.198 0.949 -0.648

PTCT Price Target

For more insight on analysts targets of PTCT, see our PTCT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $61.58 Average Broker Recommendation 1.77 (Moderate Buy)

PTCT Stock Price Chart Interactive Chart >

Price chart for PTCT

PTCT Price/Volume Stats

Current price $47.36 52-week high $55.58
Prev. close $47.37 52-week low $25.01
Day low $46.72 Volume 440,922
Day high $48.07 Avg. volume 845,745
50-day MA $41.72 Dividend yield N/A
200-day MA $42.22 Market Cap 3.46B

PTC Therapeutics, Inc. (PTCT) Company Bio


PTC Therapeutics is a global biopharmaceutical company focused on the discovery, development and commercialization of orally administered, proprietary small molecule drugs targeting an area of RNA biology we refer to as post-transcriptional control. The company was founded in 1998 and is based in South Plainfield, New Jersey.


PTCT Latest News Stream


Event/Time News Detail
Loading, please wait...

PTCT Latest Social Stream


Loading social stream, please wait...

View Full PTCT Social Stream

Latest PTCT News From Around the Web

Below are the latest news stories about PTC THERAPEUTICS INC that investors may wish to consider to help them evaluate PTCT as an investment opportunity.

PTC Therapeutics: Overdependence On One Asset, Poor Cash Management (NASDAQ:PTCT)

PTC is a commercial stage small cap surviving on a timely loan and their revenue stream is overdependent on 1 franchise. See what makes PTCT stock unattractive to me.

Seeking Alpha | January 30, 2023

NICE Recommends Reimbursement for Translarna™

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the National Institute for Health and Care Excellence (NICE) has issued a Final Evaluation Document recommending Translarna™ (ataluren) for reimbursement and use across the National Health Service (NHS) in England and Wales. Translarna is the only approved treatment for patients with nonsense mutation Duchenne muscular dystrophy aged 2 years and older who can walk.

Yahoo | January 19, 2023

PTC Therapeutics Launches 9th Annual STRIVE™ Awards Program to Fund Initiatives Benefitting the Duchenne Muscular Dystrophy Community

- 2023 Program to Focus on Innovation and Transition to Adulthood Initiatives – - Submissions Due March 17, 2023 - SOUTH PLAINFIELD, N.J., Jan. 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced the launch of the ninth annual STRIVE™ awards program. Through…

PR Newswire | January 17, 2023

A stock that deserves closer examination: PTC Therapeutics Inc. (PTCT)

A share of PTC Therapeutics Inc. (NASDAQ:PTCT) closed at $45.72 per share on Wednesday, up from $44.36 day before. While PTC Therapeutics Inc. has overperformed by 3.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, PTCT rose by 14.21%, with highs and lows ranging from $55.58 […]

US Post News | January 12, 2023

PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH PLAINFIELD, N.J., Jan. 11, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on Jan. 5, 2023, the company approved non-statutory stock options to purchase an aggregate of 39,585 shares of its common stock and 13,045 restricted stock units ("RSUs"), each…

PR Newswire | January 11, 2023

Read More 'PTCT' Stories Here

PTCT Price Returns

1-mo 24.11%
3-mo 37.51%
6-mo -11.48%
1-year 20.20%
3-year -9.36%
5-year 92.05%
YTD 24.08%
2022 -4.17%
2021 -34.74%
2020 27.07%
2019 39.95%
2018 105.76%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7506 seconds.